Imugene reveals positive imaging data for oncolytic virotherapy candidate CHECKvacc
Clinical stage immune-oncology company Imugene (ASX: IMU) has revealed what it describes as positive imaging data on its oncolytic virotherapy candidate CHECKvacc in treating metastatic triple-negative breast cancer.